We are live on ! Find out more
ORTX

Orchard Therapeutics plc American Depositary Shares
ORTX

Delisted

ORTX was delisted on the 23rd of January, 2024.

Back to rankings

47 hedge funds and large institutions have $24.7M invested in Orchard Therapeutics plc American Depositary Shares in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% less funds holding

Funds holding: 50 → 47 (-3)

18% less capital invested

Capital invested by funds: $30.2M → $24.7M (-$5.56M)

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

25% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 12

Holders
47
Holders Change
-3
Holders Change %
-6%
% of All Funds
0.81%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
9
Reduced
12
Closed
10
Calls
$6K
Puts
–
Net Calls
+$6K
Net Calls Change
-$4K

Top Buyers

Rank Fund Capital Flow
1
CA
CHI Advisors
New York
+$1.49M
2
Citadel Advisors
Citadel Advisors
Florida
+$1.26M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$466K
4
Renaissance Technologies
Renaissance Technologies
New York
+$306K
5
MIAN
Mariner Independent Advisor Network
Kansas
+$288K

Top Sellers

Rank Fund Capital Flow
1
Artisan Partners
Artisan Partners
Wisconsin
-$1.94M
2
RCM
RA Capital Management
Massachusetts
-$1.78M
3
JP Morgan Chase
JP Morgan Chase
New York
-$765K
4
UOC
UBS O'Connor
Illinois
-$368K
5
GCP
GSA Capital Partners
United Kingdom
-$360K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$4.31M – – –
Federated Hermes
2
Federated Hermes
Pennsylvania
$4.2M +$51.1K +9,183 +1%
CA
3
CHI Advisors
New York
$3.99M +$1.49M +267,965 +50%
DM
4
Deerfield Management
New York
$3.48M – – –
Temasek Holdings
5
Temasek Holdings
Singapore
$2.16M – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$1.27M +$306K +54,915 +28%
Citadel Advisors
7
Citadel Advisors
Florida
$1.15M +$1.26M +226,893 +10,598%
TCM
8
Tang Capital Management
California
$1M – – –
AG
9
Artal Group
Luxembourg
$902K – – –
Acadian Asset Management
10
Acadian Asset Management
Massachusetts
$549K +$466K +83,691 +320%
BlackRock
11
BlackRock
New York
$356K -$12K -2,155 -3%
MIAN
12
Mariner Independent Advisor Network
Kansas
$258K +$288K +51,698 New
UOC
13
UBS O'Connor
Illinois
$216K -$368K -66,094 -60%
Millennium Management
14
Millennium Management
New York
$179K +$98.8K +17,741 +98%
Morgan Stanley
15
Morgan Stanley
New York
$149K -$36.2K -6,507 -18%
CAM
16
Cormorant Asset Management
Massachusetts
$128K – – –
JP Morgan Chase
17
JP Morgan Chase
New York
$111K -$765K -137,406 -86%
FA
18
Forefront Analytics
Pennsylvania
$54K +$4.12K +740 +8%
Bank of America
19
Bank of America
North Carolina
$36K -$8.11K -1,456 -17%
Verition Fund Management
20
Verition Fund Management
Connecticut
$25K – – –
Jane Street
21
Jane Street
New York
$23K +$25.6K +4,595 New
Two Sigma Investments
22
Two Sigma Investments
New York
$18K +$9.21K +1,655 +83%
Balyasny Asset Management
23
Balyasny Asset Management
Illinois
$17K +$18.8K +3,372 New
Geode Capital Management
24
Geode Capital Management
Massachusetts
$13K – – –
BCV
25
Banque Cantonale Vaudoise
Switzerland
$12K – – –
1
2 3

ORTX Hedge Fund Activity: Q3 2022 in Review

47 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q3 2022, worth a combined $24.7M — down 18% from $30.2M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of ORTX and 8 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 9 added.

The largest buyer was CHI Advisors, adding an estimated $1.49M. The largest seller was Artisan Partners, exiting entirely with an estimated $1.94M sold.

  • 47 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q3 2022, down from 50 in Q2 2022.
  • Funds reported $24.7M of Orchard Therapeutics plc American Depositary Shares stock for Q3 2022, down 18% quarter-over-quarter.
  • 8 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q3 2022 and 10 closed out, a net change of -2 holders.
  • The largest Orchard Therapeutics plc American Depositary Shares buyer in Q3 2022 was CHI Advisors, an estimated $1.49M added.
  • The largest Orchard Therapeutics plc American Depositary Shares seller in Q3 2022 was Artisan Partners, an estimated $1.94M sold.

Based on aggregated 13F filings for Q3 2022.